⌘K
t
Evgen Pharma plc announced on 14 July 2022 that CEO Dr Huw Jones and CFO Richard Moulson will provide a live post-AGM presentation on 21 July 2022 at 3:30pm BST. This presentation, accessible via the Investor Meet Company platform, is open to all existing and potential shareholders, who can submit questions until 9am the day before the event.
| Date | 14 Jul 2022 |
| Time | 12:43:38 |
| Category | Miscellaneous |
| ID | 5162S |
Evgen Pharma plc
("Evgen" or the "Company)
Investor presentation
14 July 2022, Alderley, Cheshire - Evgen Pharma plc announces that Dr Huw Jones, CEO and Richard Moulson, CFO will provide a live post-AGM presentation via the Investor Meet Company platform on 21 July 2022 at 3:30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company free of charge and add to meet Evgen via this link: https://www.investormeetcompany.com/evgen-pharma-plc/register-investor
Investors who already follow Evgen on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
Evgen Pharma plc |
Tel: +44 1625 466591 |
|
Dr Huw Jones, CEO |
|
|
Richard Moulson, CFO |
|
|
|
|
|
FinnCap (Nominated Advisor and Broker) |
Tel: +44 20 7220 0500 |
|
Geoff Nash / Teddy Whiley (Corporate Finance) |
|
|
Alice Lane/Nigel Birks (ECM) |
|
|
|
|
|
Instinctif Partners |
Tel: +44 207 457 2020 |
|
Melanie Toyne-Sewell / Rozi Morris |
Evgen@Instinctif.com |
|
Agnes Stephens / Adam Loudon |
|
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. It will be entering the clinic in glioma/glioblastoma later in 2022. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com